Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.

Clinical trial NCT06018688 · NOT_YET_RECRUITING

Trial details

NCT number: NCT06018688
Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Non Small Cell Lung Cancer EGFR Gene Mutation

Start date: 2023-09-15
Primary completion: 2026-03-01
Enrollment: 44

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.